Go Pro
→ Why I believe the AI market will split in Q4 (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.40
+0.0%		$0.40
$0.23
▼
$15.00
$66.54M-0.173,515 shs46,883 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.51
-0.3%		$0.50
$0.28
▼
$2.06
$17.18M0.33210,204 shs113,854 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$0.77
-3.1%		$0.80
$0.69
▼
$2.18
$68.56M1.37370,458 shs441,403 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.18
$2.25
$2.09
▼
$3.44
$66.46M0.8550,952 shs40,035 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.03%0.00%+26.98%-38.46%+39,999,900.00%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-0.27%+4.63%+1.52%-5.34%-29.73%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-3.07%+9.71%-3.71%-17.65%-31.22%
XBiotech Inc. stock logo
XBIT
XBiotech
0.00%+1.40%-5.63%-6.44%-25.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.40
+0.0%		$0.40
$0.23
▼
$15.00
$66.54M-0.173,515 shs46,883 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.51
-0.3%		$0.50
$0.28
▼
$2.06
$17.18M0.33210,204 shs113,854 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$0.77
-3.1%		$0.80
$0.69
▼
$2.18
$68.56M1.37370,458 shs441,403 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.18
$2.25
$2.09
▼
$3.44
$66.46M0.8550,952 shs40,035 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.03%0.00%+26.98%-38.46%+39,999,900.00%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-0.27%+4.63%+1.52%-5.34%-29.73%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-3.07%+9.71%-3.71%-17.65%-31.22%
XBiotech Inc. stock logo
XBIT
XBiotech
0.00%+1.40%-5.63%-6.44%-25.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.00
Hold$3.00485.14% Upside
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
2.25
Hold$6.00678.92% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest KTTA, RNTX, ALPS, and XBIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/14/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/1/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/3/2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/20/2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$4.00
7/17/2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
$4.86M13.70N/AN/A($3.10) per share-0.13
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$2.39 per shareN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.06 per share13.90($1.07) per shareN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$4.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$2.01M$0.331.21N/AN/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$20.43M-$1.58N/AN/AN/AN/A-49.49%-46.81%11/12/2026 (Estimated)
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$49.87M-$1.72N/AN/AN/AN/AN/A-63.69%N/A
XBiotech Inc. stock logo
XBIT
XBiotech
-$45.54M-$1.48N/AN/AN/AN/A-31.62%-30.29%N/A

Latest KTTA, RNTX, ALPS, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$0.16-$0.16N/A-$0.16$0.30 millionN/A
8/14/2026Q2 2026
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.27-$0.10+$0.17-$0.10N/AN/A
8/13/2026Q2 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.03-$0.22-$0.25-$0.22$7.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/A
0.36
0.27
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
26.25
26.25
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
4.27
4.27
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
33.15
33.15

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
25.52%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
1.50%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
1.50%
XBiotech Inc. stock logo
XBIT
XBiotech
30.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
89166.40 million123.94 millionN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
533.41 million32.91 millionNot Optionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
1086.27 million84.97 millionN/A
XBiotech Inc. stock logo
XBIT
XBiotech
8730.49 million21.10 millionOptionable

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - What's Next?
September 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31024182
XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving Average - Time to Sell?
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xbiotech-nasdaq-xbit-shares-cross-below-200-day-moving-average-time-to-sell-2026-09-03/
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xbiotech-nasdaq-xbit-share-price-passes-above-50-day-moving-average-heres-what-happened-2026-08-26/
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311812/35550/en/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-treatment-of-active-axial-spondyloarthritis.html
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar
May 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xbiotechs-new-axial-spondyloarthritis-trial-puts-vilamakitug-on-investors-radar?utm_source=marketbeat.com&utm_medium=referral
XBiotech: Q4 Earnings Snapshot
March 13, 2026  |  chron.comhttps://www.chron.com/business/article/xbiotech-q4-earnings-snapshot-22075535.php
XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/xbiotech-s-new-trial-a-potential-game-changer-for-rheumatoid-arthritis-treatment/ar-AA1PitPW
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
August 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/xbiotech-inc-nasdaq-xbit-top-100425873.html
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
March 2, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
March 1, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 28, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 27, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 26, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 25, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 24, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 23, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 22, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 21, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 20, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 18, 2025  |  accessnewswire.comA
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 17, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
A quantum computing chandelier housed in glass enclosure inside a facility, with a military jet visible outside.
IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
By Jeffrey Neal Johnson | September 11, 2026

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.40 +0.00 (+0.03%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.40 -0.01 (-1.25%)
As of 09/23/2026 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.51 0.00 (-0.27%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.50 -0.01 (-2.67%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$0.77 -0.02 (-3.07%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+0.87%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.18 0.00 (0.00%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$2.18 +0.00 (+0.23%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas